Celera Genomics Acquires Full Ownership of Celera Diagnostics Joint Venture
Celera Genomics to Partner or Sell Small Molecule Drug Development Programs
Applera Corporation announced that its Board of Directors has approved a restructuring of its Celera Diagnostics joint venture, whereby, effective January 1, 2006, Celera Genomics acquired Applied Biosystems' 50 percent interest in the joint venture in exchange for a package of considerations to Applied Biosystems. Since its formation in 2001, Celera Diagnostics has been held equally by Applera's two business groups, Applied Biosystems Group and Celera Genomics Group.
Applera also announced that it has restructured its alliance with Abbott. Under the new relationship, the companies will continue to work with each other exclusively through a profit sharing arrangement between Abbott and Celera in most areas of molecular diagnostics, while both companies will also work individually outside the alliance in other selected areas.
In determining that the restructuring is in the best interests of the corporation and its stockholders, the Applera Board considered numerous factors and utilized the assistance and advice of several independent advisors. Included in the process were independent analyses of: Applied Biosystems' 50 percent interest in the joint venture; the various considerations made to Applied Biosystems in the restructuring; and the pro forma impact of the restructuring on Applied Biosystems and Celera Genomics.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Roche Diagnostics Licenses the Technology used for the LightCycler System to BIOTECON
Track and trace members of the plant microbiome with DNA barcodes
Innovative microscopy technique reveals secrets of lipid synthesis inside cells - Two-color infrared photothermal microscopy (2C-IPM) opens new avenues for long-term study of lipid metabolism in living cells
Millipore Names New VP of Life Science Business Unit - John Sweeney to focus on technology development and partnerships
The deadly toxin acrolein has a useful biological role
Making a better nitrate test kit
Novel Laser Technology for Microchip-Size Chemical Sensors
Microorganisms build the best fuel efficient hydrogen cells
Click... Resistant bacteria caught in the act! - Scientists have succeeded in capturing unique images of protein soldiers that help bacteria resist drugs
A powder to enhance NMR signals - Towards fast and accurate structure determination by NMR and early cancer diagnosis by MRI